Midas Management Corp maintained its position in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,000 shares of the company’s stock at the end of the second quarter. Midas Management Corp’s holdings in Johnson & Johnson were worth $1,455,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. State Street Corp lifted its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the period. Harbour Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 13,327.8% during the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares in the last quarter. Korea Investment CORP increased its holdings in shares of Johnson & Johnson by 38.9% during the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after acquiring an additional 596,134 shares in the last quarter. Bank of Nova Scotia increased its holdings in shares of Johnson & Johnson by 94.5% during the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $65,598,000. 66.06% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (JNJ) opened at 140.00 on Tuesday. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35. The company’s 50-day moving average price is $135.51 and its 200-day moving average price is $131.58. The stock has a market cap of $375.76 billion, a PE ratio of 24.35 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.68 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post $7.28 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s payout ratio is 58.33%.
JNJ has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Cowen and Company restated an “outperform” rating and set a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. UBS AG restated a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Jefferies Group LLC boosted their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 16th. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $143.70.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.